×
For best experience we recommend to activate Javascript in your browser.
TIM3 antibody (AA 22-202)
This anti-TIM3 antibody is a Mouse Monoclonal antibody detecting TIM3 in WB, IHC, IP and ICC. Suitable for Human.
Quick Overview for TIM3 antibody (AA 22-202) (ABIN7619059)
Target
See all TIM3 (TIM 3) Antibodies
TIM3 (TIM 3)
(Hepatitis A Virus Cellular Receptor 2 (TIM 3))
Reactivity
All reactivities for TIM3 antibodies
Human
Host
All hosts for TIM3 antibodies
Mouse
Clonality
All clonalities for TIM3 antibodies
Monoclonal
Conjugate
All conjugates for TIM3 antibodies
This TIM3 antibody is un-conjugated
Application
All applications for TIM3 antibodies
Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
Clone
C10
Product Details anti-TIM3 Antibody
(hide)
Binding Specificity
All epitopes for TIM3 antibodies
AA 22-202
Purpose
Hepatitis A Virus Cellular Receptor 2 (HAVCR2) Monoclonal Antibody
Sequence
Ser22~Gly202
Characteristics
The Hepatitis A Virus Cellular Receptor 2 (HAVCR2) Monoclonal Antibody (Species: Human) has been validated for the following applications: WB, IHC, ICC, IP.
Purification
Protein A + Protein G affinity chromatography
Isotype
IgG2b kappa
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
1 mg/mL
Buffer
0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
Expiry Date
12 months
Target Details for TIM3
(hide)
Target
TIM3 (TIM 3)
(Hepatitis A Virus Cellular Receptor 2 (TIM 3))
Alternative Name
HAVCR2
Gene ID
84868
UniProt
Q8TDQ0
Pathways
Regulation of Lipid Metabolism by PPARalpha , Cancer Immune Checkpoints
Recently viewed
(hide)
Chat with us , powered by LiveChat